Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody drug conjugates
Pharma
Gilead writes $2.4B off Trodelvy as CEO underscores focus
Despite the $2.4 billion impairment charge, Gilead believes Trodelvy has a future in NSCLC.
Angus Liu
Apr 26, 2024 11:21am
Novo, Novartis, Merck KGaA, Kyowa Kirin—Fierce Pharma Asia
Mar 22, 2024 8:45am
Merck’s Lynparza-Keytruda plan sputters in 2nd lung cancer trial
Mar 21, 2024 10:28am
With GSK's 2nd Blenrep win, analysts see blockbuster comeback
Mar 7, 2024 10:14am
Pfizer stops buildout of Seagen plant, affecting 120 workers
Mar 4, 2024 11:51am
Pfizer eyes 8 blockbuster cancer drugs in new oncology plan
Feb 29, 2024 5:42pm